Universidad de Murcia   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Avda Spain (1272)

Organization Overview

First Clinical Trial
2007
NCT00543127
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

CEBAS-CSIC, Murcia, Spain | Hospital Universitario Virgen Arrixaca | Hospital Universitario Virgen de la Arrixaca | Hospital Virgen de la Arrixaca | Ignacio Alejandro Astudillo Ganora | Instituto Murciano de Investigación Biosanitaria Virgen de la Arrixaca | Jose Antonio Garcia Vidal | Murcia University | Universidad de Murcia | University of Murcia (Spain) | Virgen de la Arrixaca Hospital | Virgen de la Arrixaca University Hospital, Murcia, Spain

Active Ingredients

Drugs in Phase 4 Trials (9)

capecitabine (xeloda) (1 trial)

chlorhexidine (hibitane) (2 trials)

ciprofloxacin (cipro) (1 trial)

Dexketoprofen (1 trial)

fosfomycin (monurol) (1 trial)

gemcitabine (gemzar) (2 trials)

sodium chloride (2 trials)

testosterone (delatestryl) (1 trial)

tromethamine (tham) (1 trial)

Drugs in Phase 3 Trials (12)

alteplase (Activase) (1 trial)

anastrozole (arimidex) (1 trial)

chamaemelum nobile (1 trial)

cisplatin (platinol) (1 trial)

colchicine (colbenemid) (2 trials)

etoricoxib (Gencox) (1 trial)

fulvestrant (faslodex) (1 trial)

hyaluronic acid (2 trials)

midazolam (versed) (1 trial)

neostigmine (bloxiverz) (1 trial)

sevoflurane (ultane) (1 trial)

sugammadex (bridion) (1 trial)

Drugs in Phase 2 Trials (7)

allogeneic adipose derived mesenchymal stem cell (2 trials)

bendamustine (treanda) (2 trials)

mitoxantrone (novantrone) (1 trial)

oxaliplatin (eloxatin) (1 trial)

rituximab (rituxan) (2 trials)

trifolium pratense (1 trial)

urea (2 trials)

Drugs in Phase 1 Trials (4)

allogeneic mesenchymal stem cells (1 trial)

amniotic membrane (1 trial)

autologous mononuclear stem cell (1 trial)

fucosylated autologous bone marrow cells (1 trial)

Drugs in Other Trials (11)

arabinoxylan (1 trial)

beetroot juice (1 trial)

beta-glucans (1 trial)

bifidobacterium rhamnosus (1 trial)

hydrogen peroxide (1 trial)

hydroxymethylbutyrate (1 trial)

lactobacillus rhamnosus (1 trial)

melatonin (1 trial)

olive (1 trial)

polyphenols (1 trial)

povidone-iodine (betadine) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Pain (Phase 4)

Aggression (Phase 2)

Amyotrophic Lateral Sclerosis (Phase 1)

Breast Neoplasms (Phase 3)

Carcinoma (Phase 3)

Carcinoma, Ovarian Epithelial (Phase 3)

Cholangiocarcinoma (Phase 4)

Conjunctivitis (Phase 2)

Critical Illness (Phase 3)

Fallopian Tube Neoplasms (Phase 3)

Fluoride Poisoning (Phase 3)

Heart Failure (Phase 4)

Klatskin Tumor (Phase 4)

Lymphoma (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Lymphoma, Mantle-Cell (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Motor Neuron Disease (Phase 1)

Osteoarthritis (Phase 2)

Osteoarthritis, Knee (Phase 2)

Osteonecrosis (Phase 1)

Osteoporosis (Phase 1)

Ovarian Neoplasms (Phase 3)

Peri-Implantitis (Phase 4)

Peritoneal Neoplasms (Phase 3)

Poisoning (Phase 3)

Retinitis (Phase 1)

Retinitis Pigmentosa (Phase 1)

Sclerosis (Phase 1)

Spinal Fractures (Phase 1)

Spondylitis (Phase 3)

Spondylitis, Ankylosing (Phase 3)

Urinary Tract Infections (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 33
  • # of Trial APIs: 43